Acadia Pharma (ACAD) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Acadia Pharmaceuticals (ACAD) Bullish Stance Reiterated at Cowen; All Eyes on PDP PDUFA, ADP Enrollment
November 6, 2015 12:00 PM ESTCowen analyst Ritu Baral reiterated an Outperform rating and $50 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following Q3 results with all eyes on PDP PDUFA and ADP enrollment.
Baral commented, "ACAD reported 3Q15 earnings and elaborated on initial steps for upcoming commercial... More
Piper Jaffray Downgrades Acadia Pharmaceuticals (ACAD) to Neutral
November 6, 2015 9:43 AM ESTPiper Jaffray downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Overweight to Neutral with a price target of $39.00 (from $48.00).
Analyst Charles Duncan commented, "We're downgrading to Neutral following program updates that lower our conviction on near-term upside from the pima pipeline. New concerns center on a... More
